Study of 0.4% povidone-iodine nasal spray for SARS-CoV-2
Evaluatig the virucidal efficacy of 0.4% povidone-iodine nasal spray against SARS-CoV-2 in the patients’ nasopharynx at 3 minutes, 4 hours after PVP-I exposure.
Stay updated with breaking news from Updated Guidelines. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Evaluatig the virucidal efficacy of 0.4% povidone-iodine nasal spray against SARS-CoV-2 in the patients’ nasopharynx at 3 minutes, 4 hours after PVP-I exposure.
On 31st August 2022, the Federal Ministry of Interior (‘MOI’) released the Revised Handbook for Expatriate Quota Administration in Nigeria (‘The Revised Handbook’) which took effect...
The CDC’s updated opioid prescribing guidelines include naloxone for patients on long-term opioid medication, and non-opioid pain medication for non-chronic pain
The Affordable Care Act (ACA) requires non-grandfathered group health plans (and insurers) to provide coverage for certain preventive health services for all adults, women, and...
Continuous Erector Spinae Plane Block Using Programmed Intermittent Bolus Regimen versus Intravenous Patient-Controlled Opioid Analgesia Within an Enhanced Recovery Program After Open Liver Resection in Patients with Coagulation Disorder: A Randomized, Controlled, Non-Inferiority Trial